We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
An update on vaginal oestrogen for overactive bladder: reporting the literature.
- Authors
Xiao Yun (Celina) Lin
- Abstract
Antimuscarinic medicines are widely used for treating overactive bladder syndrome in postmenopausal women experiencing urinary incontinence. However, these treatments may have undesirable effects, leading to some women to cease treatment. An alternative treatment cited in recent studies is topical oestrogen applied vaginally, which is normally a treatment for atrophic vaginitis. The aim of this paper is to provide an update on the use of vaginal oestrogen to treat symptoms of overactive bladder in post-menopausal women. A search of the literature published between 2005 and 2020 identified 10 primary studies that showed that topical oestrogen was effective in treating symptoms in terms of improving urinary incontinence symptom measures and subjective feeling. What distinguishes topical oestrogen from antimuscarinic medication is that it is well tolerated, with fewer reported adverse effects. Evidence suggests that oestrogen therapy prior to commencing pelvic floor electrical stimulation treatment or antimuscarinic medication may enhance the effect of those treatments in the longer term. It may be recommended that topical oestrogen applied vaginally be the first-line pharmacological treatment for overactive bladder symptoms in post-menopausal women.
- Publication
Australian & New Zealand Continence Journal, 2021, Vol 27, Issue 2, p40
- ISSN
1448-0131
- Publication type
Academic Journal
- DOI
10.33235/anzcj.27.2.40-46